Genzyme ($GENZ) last week cut 392 filled and unfilled jobs at several locations, executing the first step in its plan to eliminate 1,000 by the end of next year. Employees got the word on Thursday.
The 1,000 represents about one-twelfth of the Cambridge, MA, biotech's workforce.
Some 185 of those cuts are in Massachusetts, but not at the troubled Allston manufacturing plant. The plant is currently operating under a consent decree with the FDA for remediation of manufacturing shortcomings. The company has been and continues to hire manufacturing and quality assurance employees, says the Boston Globe. Plans call for an additional 500 to 600 such jobs in Allston, Framingham, and elsewhere by the end of next year.